Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 627-872-0 | CAS number: 1514-82-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In this 90 day study, the NOAEL was considered to be 199 ppm (eq. 1424.90 mg/m3) based on chronic heart inflammation, clinical signs and histopathological changes related to irritation of the respiratory tract, CNS effects and histopathological changes seen in the liver, pancreas, spleen and thymus. Following the 4 week recovery period, there was partial or complete recovery of all toxic effects.
Key value for chemical safety assessment
- Toxic effect type:
- concentration-driven
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 July 2012 to 11 January 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was conducted according to official test guidelines and in compliance with GLP; on this basis the study is considered reliable without restrictions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.29 (Sub-Chronic Inhalation Toxicity:90-Day Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD (SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation:47 to 54 days
- Weight at study initiation: in the range of 216 to 263 g for males and 160 to 224 g for females.
- Housing: housed five of one sex per cage made of a polycarbonate body with a stainless steel mesh lid.
- Diet:free access
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):19 to 23°C
- Humidity (%):40 to 70%
- Photoperiod (hrs dark / hrs light): 12h light/12 h dark
IN-LIFE DATES: From: 10 July 2012 to 11 January 2013 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Each exposure system consisted of a Glass vaporiser and a whole body exposure chamber a 0.75 m3 chamber of stainless steel and glass construction
- Method of holding animals in test chamber: Wire mesh modular caging
- Source and rate of air: From in-house compressed air system – breathing quality
- System of generating particulates/aerosols:Aerosol Generator: Sintered glass vaporiser for Groups 2 to 4 all in a water bath set at 40°C; Syringe driver, polypropylene syringe for Group 2; Liquid reservoir and feed rate used to alter concentration Groups 3 and 4; Test groups - 30 L/min
- Temperature, humidity in air chamber: within expected parameters for this type of exposure system.
- Air flow rate: Group 1 - 149 L/min, Group 2 to 4 - 119 L/min - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test atmosphere sample (chamber) directly analysed using the IR spectrophotometer
Vapour samples collected as follows:
Sample frequency – minimum of 3 samples/group/exposure
Sample location – representative animal level
Sample position remained constant
Sample analysis by Infra-red spectrophotometer - Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 6 hours/day for 5 days each week (Monday to Friday)
- Remarks:
- Doses / Concentrations:
0, 199, 505, 2876 ppm
Basis:
analytical conc. - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
In a previous 2-week dose range finding study (Huntingdon Life Sciences Study Number: WAG0024), 3 groups of rats were exposed to 2-bromo-3,3,3-trifluoropropene for 6 hours per day, 5 days per week at achieved aerosol concentrations of 533, 1167 and 2980 ppm.
There were no unscheduled deaths at doses up to 2980 ppm. In-life findings, consisting of transient clinical signs, evident during and after exposure for all treated animals, and reduced bodyweight gain and food consumption, seen for all treated males, were not considered adverse.
Histopathological changes related to treatment were seen mainly in the nasal turbinates of rats exposed to 1167 or 2980 ppm and were consistent with a localised toxic effect of the test material. No histopathological changes were evident at 533 ppm and this was considered to be the no observed adverse effect level (NOAEL).
Although adverse histopathological findings were evident at 1167 ppm it was considered that these may not progress over 13 weeks and may be readily reversible during a 4 week off-exposure recovery period. A target high exposure level of 3000 ppm was thus selected for this study, as it was considered that exposure for 13 weeks at this level would have adverse histopathological effects on rats which may or may not be reversible.
The target intermediate exposure level of 500 ppm was selected as it was shown to have no adverse effects after 2 weeks exposure.
Since the 500 and 3000 ppm target exposure levels were used on the 2-week study, their use on the 13-week study would also enable the relationship of changes over time to be explored.
The target low exposure level of 200 ppm was expected to have no adverse effects and would offer an acceptable worker safety margin.
- Post-exposure recovery period in satellite groups:
Ten male and ten female rats were assigned to each of the Control and high dose groups. These animals were treated for 13 weeks, followed by a 4 week period without treatment to assess recovery from any treatment related effect. - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS : Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations:one week before treatment commenced (Week -1), on the day that treatment commenced (Week 0), weekly throughout the treatment and recovery periods, and before necropsy.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Before treatment and during week 13
- Dose groups that were examined: Groups 1 (Control) and 4 (2876 ppm)
HAEMATOLOGY: Yes
- Time schedule for collection of blood: during week 13 of treatment and week 4 of recovery
- Anaesthetic used for blood collection: isoflurane
- Animals fasted: Yes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood:during week 13 of treatment and week 4 of recovery (same animals as for peripheral haematology: further blood samples collected)
- Animals fasted: Yes
URINALYSIS: Yes
- Time schedule for collection of urine:During Week 13 of treatment, overnight urine samples were collected from all animals.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
NEUROBEHAVIOURAL EXAMINATION: Yes (ARENA OBSERVATIONS)
- Time schedule for examinations: weekly - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Animals killed during the study, animal killed after 13 weeks of treatment or 4 weeks of recovery were subjected to a detailed necroscopy
ORGAN WEIGHTS: Yes
HISTOPATHOLOGY: Yes
All tissues preserved for examination were examined for all animals of Groups 1 (Control) and 4 (2876 ppm) sacrificed on completion of the scheduled treatment period and for all animals killed or dying during the study.
Nasal turbinates, larynx, lungs, trachea (including bifurcation), heart, liver, pancreas, spleen, thymus, teeth and abnormalities preserved for examination were examined for all animals of Group 2 (199 ppm), Group 3 (505 ppm) and all recovery animals sacrificed on completion of the scheduled treatment period.
Tissues reported at macroscopic examination as being grossly abnormal were examined for Main and Recovery animals - Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Treatment-related, but transient, clinical signs, related to inhalation of an irritant material (shallow breathing, piloerection, grinding teeth and hunched posture) or possible CNS effects (unresponsiveness to external stimuli, underactivity, and partially closed eyelids), were evident during and after exposure at all exposure levels. Reductions in grip strength and motor activity were evident for animals exposed to 505 or 2876 ppm and were only partially reversible for animals previously exposed to 2876 ppm after a 4 week recovery period.
BODY WEIGHT AND WEIGHT GAIN AND FOOD CONSUMPTION
Lower bodyweight gain was evident, over the 13 week treatment period, for treated males and females exposed to 505 ppm or higher, in a dosage related manner. Total food consumption was similarly lower for treated males and females exposed to 2876 ppm.
Effects on bodyweight and food consumption showed evidence of recovery for animals
previously exposed to 2876 ppm after a 4 week recovery period.
OPHTHALMOSCOPIC EXAMINATION
Ophthalmic examination revealed no treatment-related effects.
HAEMATOLOGY
Week 13 group mean total white blood cell counts were lower than control for males and females exposed to 2876 ppm (0.78 and 0.68X control respectively), statistically significantly so for females. This was mainly as a result of statistically significantly lower lymphocytes counts (0.68 and 0.66X control for males and females exposed to 2876 ppm, respectively). During Week 4 of recovery, differences from control for total white blood cell and lymphocyte counts remained similar to Week 13 values for both sexes previously exposed to 2876 ppm.
Eosinophil counts were statistically significantly lower than control for all treated animals, with evidence of a dose-related response (0.26 to 0.47X and 0.27 to 0.64X control for males and females exposed to 199 and 2876 ppm respectively). However, during Week 4 of recovery eosinophil counts showed evidence of some recovery to control values.
Monocyte counts were statistically significantly higher than control for males and females exposed to 505 and 2876 ppm (1.74 and 1.84X control for males, and 2.16 and 1.68X control for females respectively). However, during Week 4 of recovery monocyte counts were lower than control values for both sexes previously exposed to 2876 ppm.
CLINICAL CHEMISTRY
Week 13 mean alkaline phosphatase (ALP) values for males and females exposed to 2876 ppm were statistically significantly higher (1.32 and 1.43x control, respectively). During Week 4 of recovery, values for males previously exposed to 2876 ppm were unchanged. However, for females of the same group, values had lowered and were similar to Week 13 control values.
Group mean values for aspartate amino transferase (AST) were statistically significantly higher than control for treated males (2.31, 3.00 and 2.88X with ascending dose), and females exposed to 505 ppm (2.72X control). There was considerable intragroup variation for this parameter. However, the group mean changes seen were outside the range of available background data. During Week 4 of recovery, values for both sexes previously exposed to 2876 ppm were similar to controls.
Group mean values for urea were statistically significantly higher than control for treated females (1.18, 1.24 and 1.54X control with ascending dose), and males exposed to 505 and 2876 ppm (1.25 and 1.64X control, respectively).Group mean phosphate values were statistically significantly higher for treated females (1.42, 1.75 and 2.38X control, with ascending dose) and males exposed to 2876 ppm (1.30X control). During Week 4 of recovery, urea values for both sexes previously exposed to 2876 ppm had returned to control values.
URINALYSIS: no treatment-related effects
NEUROBEHAVIOUR
Sensory reactivity observations for males and females were unaffected.
During Week 13 of treatment grip strength values were statistically significantly reduced for animals exposed to 2876 ppm (forelimbs and hindlimbs) and in males exposed to 505 ppm (hindlimbs only). Grip strength for animals exposed to 199 ppm and for females exposed to 505 ppm was unaffected. Forelimb grip strength values for animals previously exposed to 2876 ppm were similar to those of controls during Week 4 of recovery but hindlimb values were still low, although to a lesser extent than during Week 13 of treatment.
High beam and low beam motor activity scores (rearing and cage floor activity respectively) were consistently reduced in animals exposed to 2876 ppm throughout most of the 1-hour recording period during Week 13 of treatment. High beam scores for animals exposed to 505 ppm were also reduced, as, to a lesser extent, were low beam scores for females exposed to 505 ppm, with a dose-relationship being evident. Motor activity for animals exposed to 199 ppm was unaffected. Low beam scores for females previously exposed to 2876 ppm were again low compared with control scores during Week 4 of recovery but the differences were less marked than during Week 13 of treatment. High and low beam scores for males previously exposed to 2876 ppm were lower than control at a few of the 6-minute intervals (p<0.05 or 0.01) but the total activity scores over the 1-hour recording period did not attain statistical significance.
ORGAN WEIGHTS
After 13 weeks of treatment, thymus weights were statistically significantly lower for males and females exposed to 2876 ppm (0.63 and 0.54X control, respectively). However, after 4 weeks recovery, thymus weights appeared to have fully recovered to control values.
Lung and bronchi weights were slightly elevated for males exposed to 505 or 2876 ppm (1.07 and 1.12X control respectively), with similar values after 4 weeks of treatment for males previously exposed to 2876 ppm.
Salivary gland weights were statistically significantly lower than control values for all treated females (0.81, 0.82 and 0.84X control, with ascending dose). For males, a reduction in salivary gland weights was also evident (between 0.88 and 0.89X control for all treated males), however, these did not achieve statistical significance. However, after 4 weeks recovery these have recovered to control values.
GROSS PATHOLOGY
Teeth pallor was noted in all animals exposed to 2876 ppm, the majority of animals exposed to 505 ppm and a few animals exposed to 199 ppm. Thickening was seen in the majority of females and one male exposed to 2876 ppm.
Spleen capsular thickening was observed in the majority of males and some females exposed to 2876 ppm and a few animals exposed to 505 ppm. Adhesions were noted in some females exposed to 505 or 2876 ppm.
The macroscopic examination performed after 4 weeks of recovery revealed the following changes in teeth and spleen. Teeth pallor was noted in all animals exposed to 2876 ppm. Thickening was seen in occasional females and one male previously exposed to 2876 ppm.
Spleen capsular thickening was observed in one male previously exposed to 2876 ppm. Adhesions were noted in some males and one female previously exposed to 2876 ppm.
HISTOPATHOLOGY: NON-NEOPLASTIC
Histopathological changes related to treatment were seen in the liver (centrilobular hepatocyte hypertrophy), pancreas (acinar cell degranulation), heart (chronic inflammation), spleen (capsular inflammation and/or thickening and adhesion), thymus (involution/atrophy), nasal turbinates (findings related to minor local irritants), larynx (ventral squamous metaplasia) and teeth (pulp cavity necrosis). The majority of these findings were seen with animals at 505 and 2876 ppm. Chronic inflammation in the heart and acinar cell degranulation in the pancreas were evident for animals exposed to 199 ppm, however, these changes are not considered to be adverse. The slight and moderate degrees of chronic inflammation in the heart observed at 505 and 2876 ppm are considered adverse.
Following the 4 week recovery period, there was complete recovery of test material related histopathological changes seen in the liver, pancreas, heart, thymus, larynx and teeth and partial recovery for the findings see in the spleen (capsular inflammation and/or thickening) and nasal turbinates (atrophy/disorganisation/vacuolation of the olfactory epithelium and nasolacrimal duct inflammation). - Dose descriptor:
- NOAEC
- Effect level:
- 199 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Critical effects observed:
- not specified
- Conclusions:
- The test article, 2-bromo-3,3,3-trifluoropropene, was administered to 3 groups of rats by inhalation administration, using a whole-body exposure system, for 6 hours a day, 5 days a week, for 13 week at achieved aerosol concentrations of 199, 505 and 2876 ppm. Based on adverse chronic inflammation in the heart, transient clinical signs, lower bodyweight gain, food consumption, grip strength and motor activity and histopathological changes in the liver, pancreas, heart, spleen, thymus, nasal turbinates, larynx and teeth seen with animals exposed to 505 or 2876 ppm, the no observed adverse effect level (NOAEL) was considered to be 199 ppm.
Reference
In the heart, chronic inflammation was seen in males exposed to 199 ppm and both sexes exposed to 505 or 2876 ppm. The heart tissue samples from all males (main study and recovery) were independently peer reviewed by an external consultant pathologist and the findings agreed between the consultant and the study pathologist. The minimal degree observed at 199 ppm is considered unlikely to be associated with any alteration of heart function and is considered not adverse. The slight and moderate degrees observed at 505 and 2876 ppm are considered adverse. This change may be related to the elevated alkaline phosphatase and aspartate amino transferase levels measured during Week 13 of exposures, however the toxicological importance of this is unclear. Complete recovery of the chronic inflammation was seen following the 4 week recovery period.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 1 424.9 mg/m³
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The key study, referred to above, was considered reliable without restriction; the overall database is therefore considered to be of acceptable quality.
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 10 July 2012 to 11 January 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was conducted according to official test guidelines and in compliance with GLP; on this basis the study is considered reliable without restrictions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.29 (Sub-Chronic Inhalation Toxicity:90-Day Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD (SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation:47 to 54 days
- Weight at study initiation: in the range of 216 to 263 g for males and 160 to 224 g for females.
- Housing: housed five of one sex per cage made of a polycarbonate body with a stainless steel mesh lid.
- Diet:free access
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):19 to 23°C
- Humidity (%):40 to 70%
- Photoperiod (hrs dark / hrs light): 12h light/12 h dark
IN-LIFE DATES: From: 10 July 2012 to 11 January 2013 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Each exposure system consisted of a Glass vaporiser and a whole body exposure chamber a 0.75 m3 chamber of stainless steel and glass construction
- Method of holding animals in test chamber: Wire mesh modular caging
- Source and rate of air: From in-house compressed air system – breathing quality
- System of generating particulates/aerosols:Aerosol Generator: Sintered glass vaporiser for Groups 2 to 4 all in a water bath set at 40°C; Syringe driver, polypropylene syringe for Group 2; Liquid reservoir and feed rate used to alter concentration Groups 3 and 4; Test groups - 30 L/min
- Temperature, humidity in air chamber: within expected parameters for this type of exposure system.
- Air flow rate: Group 1 - 149 L/min, Group 2 to 4 - 119 L/min - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test atmosphere sample (chamber) directly analysed using the IR spectrophotometer
Vapour samples collected as follows:
Sample frequency – minimum of 3 samples/group/exposure
Sample location – representative animal level
Sample position remained constant
Sample analysis by Infra-red spectrophotometer - Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 6 hours/day for 5 days each week (Monday to Friday)
- Remarks:
- Doses / Concentrations:
0, 199, 505, 2876 ppm
Basis:
analytical conc. - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
In a previous 2-week dose range finding study (Huntingdon Life Sciences Study Number: WAG0024), 3 groups of rats were exposed to 2-bromo-3,3,3-trifluoropropene for 6 hours per day, 5 days per week at achieved aerosol concentrations of 533, 1167 and 2980 ppm.
There were no unscheduled deaths at doses up to 2980 ppm. In-life findings, consisting of transient clinical signs, evident during and after exposure for all treated animals, and reduced bodyweight gain and food consumption, seen for all treated males, were not considered adverse.
Histopathological changes related to treatment were seen mainly in the nasal turbinates of rats exposed to 1167 or 2980 ppm and were consistent with a localised toxic effect of the test material. No histopathological changes were evident at 533 ppm and this was considered to be the no observed adverse effect level (NOAEL).
Although adverse histopathological findings were evident at 1167 ppm it was considered that these may not progress over 13 weeks and may be readily reversible during a 4 week off-exposure recovery period. A target high exposure level of 3000 ppm was thus selected for this study, as it was considered that exposure for 13 weeks at this level would have adverse histopathological effects on rats which may or may not be reversible.
The target intermediate exposure level of 500 ppm was selected as it was shown to have no adverse effects after 2 weeks exposure.
Since the 500 and 3000 ppm target exposure levels were used on the 2-week study, their use on the 13-week study would also enable the relationship of changes over time to be explored.
The target low exposure level of 200 ppm was expected to have no adverse effects and would offer an acceptable worker safety margin.
- Post-exposure recovery period in satellite groups:
Ten male and ten female rats were assigned to each of the Control and high dose groups. These animals were treated for 13 weeks, followed by a 4 week period without treatment to assess recovery from any treatment related effect. - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS : Yes
- Time schedule: weekly
BODY WEIGHT: Yes
- Time schedule for examinations:one week before treatment commenced (Week -1), on the day that treatment commenced (Week 0), weekly throughout the treatment and recovery periods, and before necropsy.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Before treatment and during week 13
- Dose groups that were examined: Groups 1 (Control) and 4 (2876 ppm)
HAEMATOLOGY: Yes
- Time schedule for collection of blood: during week 13 of treatment and week 4 of recovery
- Anaesthetic used for blood collection: isoflurane
- Animals fasted: Yes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood:during week 13 of treatment and week 4 of recovery (same animals as for peripheral haematology: further blood samples collected)
- Animals fasted: Yes
URINALYSIS: Yes
- Time schedule for collection of urine:During Week 13 of treatment, overnight urine samples were collected from all animals.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
NEUROBEHAVIOURAL EXAMINATION: Yes (ARENA OBSERVATIONS)
- Time schedule for examinations: weekly - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Animals killed during the study, animal killed after 13 weeks of treatment or 4 weeks of recovery were subjected to a detailed necroscopy
ORGAN WEIGHTS: Yes
HISTOPATHOLOGY: Yes
All tissues preserved for examination were examined for all animals of Groups 1 (Control) and 4 (2876 ppm) sacrificed on completion of the scheduled treatment period and for all animals killed or dying during the study.
Nasal turbinates, larynx, lungs, trachea (including bifurcation), heart, liver, pancreas, spleen, thymus, teeth and abnormalities preserved for examination were examined for all animals of Group 2 (199 ppm), Group 3 (505 ppm) and all recovery animals sacrificed on completion of the scheduled treatment period.
Tissues reported at macroscopic examination as being grossly abnormal were examined for Main and Recovery animals - Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Treatment-related, but transient, clinical signs, related to inhalation of an irritant material (shallow breathing, piloerection, grinding teeth and hunched posture) or possible CNS effects (unresponsiveness to external stimuli, underactivity, and partially closed eyelids), were evident during and after exposure at all exposure levels. Reductions in grip strength and motor activity were evident for animals exposed to 505 or 2876 ppm and were only partially reversible for animals previously exposed to 2876 ppm after a 4 week recovery period.
BODY WEIGHT AND WEIGHT GAIN AND FOOD CONSUMPTION
Lower bodyweight gain was evident, over the 13 week treatment period, for treated males and females exposed to 505 ppm or higher, in a dosage related manner. Total food consumption was similarly lower for treated males and females exposed to 2876 ppm.
Effects on bodyweight and food consumption showed evidence of recovery for animals
previously exposed to 2876 ppm after a 4 week recovery period.
OPHTHALMOSCOPIC EXAMINATION
Ophthalmic examination revealed no treatment-related effects.
HAEMATOLOGY
Week 13 group mean total white blood cell counts were lower than control for males and females exposed to 2876 ppm (0.78 and 0.68X control respectively), statistically significantly so for females. This was mainly as a result of statistically significantly lower lymphocytes counts (0.68 and 0.66X control for males and females exposed to 2876 ppm, respectively). During Week 4 of recovery, differences from control for total white blood cell and lymphocyte counts remained similar to Week 13 values for both sexes previously exposed to 2876 ppm.
Eosinophil counts were statistically significantly lower than control for all treated animals, with evidence of a dose-related response (0.26 to 0.47X and 0.27 to 0.64X control for males and females exposed to 199 and 2876 ppm respectively). However, during Week 4 of recovery eosinophil counts showed evidence of some recovery to control values.
Monocyte counts were statistically significantly higher than control for males and females exposed to 505 and 2876 ppm (1.74 and 1.84X control for males, and 2.16 and 1.68X control for females respectively). However, during Week 4 of recovery monocyte counts were lower than control values for both sexes previously exposed to 2876 ppm.
CLINICAL CHEMISTRY
Week 13 mean alkaline phosphatase (ALP) values for males and females exposed to 2876 ppm were statistically significantly higher (1.32 and 1.43x control, respectively). During Week 4 of recovery, values for males previously exposed to 2876 ppm were unchanged. However, for females of the same group, values had lowered and were similar to Week 13 control values.
Group mean values for aspartate amino transferase (AST) were statistically significantly higher than control for treated males (2.31, 3.00 and 2.88X with ascending dose), and females exposed to 505 ppm (2.72X control). There was considerable intragroup variation for this parameter. However, the group mean changes seen were outside the range of available background data. During Week 4 of recovery, values for both sexes previously exposed to 2876 ppm were similar to controls.
Group mean values for urea were statistically significantly higher than control for treated females (1.18, 1.24 and 1.54X control with ascending dose), and males exposed to 505 and 2876 ppm (1.25 and 1.64X control, respectively).Group mean phosphate values were statistically significantly higher for treated females (1.42, 1.75 and 2.38X control, with ascending dose) and males exposed to 2876 ppm (1.30X control). During Week 4 of recovery, urea values for both sexes previously exposed to 2876 ppm had returned to control values.
URINALYSIS: no treatment-related effects
NEUROBEHAVIOUR
Sensory reactivity observations for males and females were unaffected.
During Week 13 of treatment grip strength values were statistically significantly reduced for animals exposed to 2876 ppm (forelimbs and hindlimbs) and in males exposed to 505 ppm (hindlimbs only). Grip strength for animals exposed to 199 ppm and for females exposed to 505 ppm was unaffected. Forelimb grip strength values for animals previously exposed to 2876 ppm were similar to those of controls during Week 4 of recovery but hindlimb values were still low, although to a lesser extent than during Week 13 of treatment.
High beam and low beam motor activity scores (rearing and cage floor activity respectively) were consistently reduced in animals exposed to 2876 ppm throughout most of the 1-hour recording period during Week 13 of treatment. High beam scores for animals exposed to 505 ppm were also reduced, as, to a lesser extent, were low beam scores for females exposed to 505 ppm, with a dose-relationship being evident. Motor activity for animals exposed to 199 ppm was unaffected. Low beam scores for females previously exposed to 2876 ppm were again low compared with control scores during Week 4 of recovery but the differences were less marked than during Week 13 of treatment. High and low beam scores for males previously exposed to 2876 ppm were lower than control at a few of the 6-minute intervals (p<0.05 or 0.01) but the total activity scores over the 1-hour recording period did not attain statistical significance.
ORGAN WEIGHTS
After 13 weeks of treatment, thymus weights were statistically significantly lower for males and females exposed to 2876 ppm (0.63 and 0.54X control, respectively). However, after 4 weeks recovery, thymus weights appeared to have fully recovered to control values.
Lung and bronchi weights were slightly elevated for males exposed to 505 or 2876 ppm (1.07 and 1.12X control respectively), with similar values after 4 weeks of treatment for males previously exposed to 2876 ppm.
Salivary gland weights were statistically significantly lower than control values for all treated females (0.81, 0.82 and 0.84X control, with ascending dose). For males, a reduction in salivary gland weights was also evident (between 0.88 and 0.89X control for all treated males), however, these did not achieve statistical significance. However, after 4 weeks recovery these have recovered to control values.
GROSS PATHOLOGY
Teeth pallor was noted in all animals exposed to 2876 ppm, the majority of animals exposed to 505 ppm and a few animals exposed to 199 ppm. Thickening was seen in the majority of females and one male exposed to 2876 ppm.
Spleen capsular thickening was observed in the majority of males and some females exposed to 2876 ppm and a few animals exposed to 505 ppm. Adhesions were noted in some females exposed to 505 or 2876 ppm.
The macroscopic examination performed after 4 weeks of recovery revealed the following changes in teeth and spleen. Teeth pallor was noted in all animals exposed to 2876 ppm. Thickening was seen in occasional females and one male previously exposed to 2876 ppm.
Spleen capsular thickening was observed in one male previously exposed to 2876 ppm. Adhesions were noted in some males and one female previously exposed to 2876 ppm.
HISTOPATHOLOGY: NON-NEOPLASTIC
Histopathological changes related to treatment were seen in the liver (centrilobular hepatocyte hypertrophy), pancreas (acinar cell degranulation), heart (chronic inflammation), spleen (capsular inflammation and/or thickening and adhesion), thymus (involution/atrophy), nasal turbinates (findings related to minor local irritants), larynx (ventral squamous metaplasia) and teeth (pulp cavity necrosis). The majority of these findings were seen with animals at 505 and 2876 ppm. Chronic inflammation in the heart and acinar cell degranulation in the pancreas were evident for animals exposed to 199 ppm, however, these changes are not considered to be adverse. The slight and moderate degrees of chronic inflammation in the heart observed at 505 and 2876 ppm are considered adverse.
Following the 4 week recovery period, there was complete recovery of test material related histopathological changes seen in the liver, pancreas, heart, thymus, larynx and teeth and partial recovery for the findings see in the spleen (capsular inflammation and/or thickening) and nasal turbinates (atrophy/disorganisation/vacuolation of the olfactory epithelium and nasolacrimal duct inflammation). - Dose descriptor:
- NOAEC
- Effect level:
- 199 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Critical effects observed:
- not specified
- Conclusions:
- The test article, 2-bromo-3,3,3-trifluoropropene, was administered to 3 groups of rats by inhalation administration, using a whole-body exposure system, for 6 hours a day, 5 days a week, for 13 week at achieved aerosol concentrations of 199, 505 and 2876 ppm. Based on adverse chronic inflammation in the heart, transient clinical signs, lower bodyweight gain, food consumption, grip strength and motor activity and histopathological changes in the liver, pancreas, heart, spleen, thymus, nasal turbinates, larynx and teeth seen with animals exposed to 505 or 2876 ppm, the no observed adverse effect level (NOAEL) was considered to be 199 ppm.
Reference
In the heart, chronic inflammation was seen in males exposed to 199 ppm and both sexes exposed to 505 or 2876 ppm. The heart tissue samples from all males (main study and recovery) were independently peer reviewed by an external consultant pathologist and the findings agreed between the consultant and the study pathologist. The minimal degree observed at 199 ppm is considered unlikely to be associated with any alteration of heart function and is considered not adverse. The slight and moderate degrees observed at 505 and 2876 ppm are considered adverse. This change may be related to the elevated alkaline phosphatase and aspartate amino transferase levels measured during Week 13 of exposures, however the toxicological importance of this is unclear. Complete recovery of the chronic inflammation was seen following the 4 week recovery period.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 1 423.9 mg/m³
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The key study, referred to above, was considered reliable without restriction; the overall database is therefore considered to be of acceptable quality.
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No information regarding oral or dermal administration of the substance are available. Due to the physical nature of the substance (a highly volatile liquid) it is expected that no significant exposure will occur by either of these routes.
Two 14 day range finding studies and one main 90 day repeat dose toxicity study were performed by the inhalation routes.
In the main study, male and female rats received 2-bromo-3,3,3-trifluoropropene at levels of 199, 505 and 2876 ppm (achieved concentrations) 5 days per week (6 hour exposure) for 90 days followed by a 4 week period without treatment. Dose selection were based on two 14 days range finding studies which resulted in clinical signs and histopathological changes, related to inhalation of an irritant material. In the main study, there were no treatment related deaths. Treatment-related, but transient, clinical signs, related to inhalation of an irritant material (shallow breathing, piloerection, grinding teeth and hunched posture) or possible CNS effects (unresponsiveness to external stimuli, underactivity, and partially closed eyelids), were evident at all exposure levels. Reductions in grip strength and motor activity were apparent at 505 or 2876 ppm and only partially reversible for animals previously exposed to 2876 ppm after the recovery period. Lower bodyweight gain was evident, over the 13 week treatment period, for animals exposed to 505 ppm or higher. Total food consumption was similarly lower for animals exposed to 2876 ppm. Effects on bodyweight and food consumption showed evidence of recovery for animals previously exposed to 2876 ppm. Histopathological changes related to treatment were seen in the liver (centrilobular hepatocyte hypertrophy), pancreas (acinar cell degranulation), heart (chronic inflammation), spleen (capsular inflammation and/or thickening and adhesion), thymus (involution/atrophy), nasal turbinates (findings related to minor local irritants), larynx (ventral squamous metaplasia) and teeth (pulp cavity necrosis). The majority of these findings were seen with animals at 505 and 2876 ppm. Chronic inflammation in the heart and acinar cell degranulation in the pancreas were evident for animals exposed to 199 ppm, however, these changes are not considered to be adverse. The slight and moderate degrees of chronic inflammation in the heart observed at 505 and 2876 ppm are considered adverse. Following the 4 week recovery period, there was complete recovery of test material related histopathological changes seen in the liver, pancreas, heart, thymus, larynx and teeth and partial recovery for the findings see in the spleen (capsular inflammation and/or thickening) and nasal turbinates (atrophy/disorganisation/vacuolation of the olfactory epithelium and nasolacrimal duct inflammation). Based on these findings, the 90 day repeated dose inhalation study no observed adverse effect level (NOAEL) was considered to be 199 ppm.
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
Only available study however, the study was conducted according to official test guidelines and in compliance with GLP
Justification for selection of repeated dose toxicity inhalation - local effects endpoint:
Only available study however, the study was conducted according to official test guidelines and in compliance with GLP.
Repeated dose toxicity: inhalation - systemic effects (target organ) cardiovascular / hematological: heart; cardiovascular / hematological: spleen; neurologic: central nervous system
Justification for classification or non-classification
Two 14 day range finding studies and one main 90 day repeat dose toxicity study mainly showed transient toxic effects due to the narcotic and irritancy properties of the substance via the inhalation route. In the 90 day study, the NOAEL was considered to be 199 ppm (eq. 1424.90 mg/m3) based on chronic heart inflammation, clinical signs and histopathological changes related to irritation of the respiratory tract, CNS effects and histopathological changes seen in the liver, pancreas, spleen and thymus. Following the 4 week recovery period, there was partial or complete recovery of all toxic effects.The adverse toxic effects occurred at concentrations higher than the threshold cited in the CLP regulation. Therefore, 2-bromo-3,3,3-trifluoropropene should not be classified under the CLP regulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.